Inhibrx to present ordastobart plus pembrolizumab Phase 2/3 HexAgon — HN data at ESMO Congress
Inhibrx will present Phase 2/3 HexAgon-HN primary analysis for ordastobart (INBRX-106) plus pembrolizumab at ESMO on Oct. 25, 2026. Secondary efficacy data from the Phase 2 ChonDRAgon study of ozekibart (INBRX-109) in conventional chondrosarcoma will be presented Oct. 29, 2026 at MSTS. Updated subgroup and progression